再生障碍性贫血 中国就医指南

Aplastic anemia (AA) is a rare, life-threatening hematologic disorder characterized by bone marrow failure, resulting in pancytopenia—profound deficiencies of red blood cells, white blood cells, and platelets. Unlike leukemias or myelodysplastic syndromes, AA involves immune-mediated destruction or functional suppression of hematopoietic stem and progenitor cells, leading to hypocellular or acellular bone marrow without abnormal cell infiltration or fibrosis. The primary pathogenesis centers on autoreactive T-lymphocyte activation, which targets hematopoietic stem cells via cytokine-mediated apoptosis (e.g., IFN-γ and TNF-α overexpression) and Fas/FasL pathway dysregulation. In ~75% of cases, the disease is acquired, often triggered by environmental exposures—including benzene, certain medications (e.g., chloramphenicol, sulfonamides, anticonvulsants), viral infections (e.g., hepatitis viruses, Epstein-Barr virus, parvovirus B19), or idiopathic immune dysregulation. A smaller subset (<10%) arises from inherited bone marrow failure syndromes such as Fanconi anemia, Dyskeratosis congenita, or Shwachman-Diamond syndrome, typically presenting in childhood with associated physical anomalies and cancer predisposition. Epidemiologically, AA affects approximately 2–7 new cases per million people annually worldwide, with a bimodal age distribution peaking in adolescence/early adulthood (15–25 years) and again after age 60. Incidence is notably higher in East Asia, particularly China, where rates reach up to 10–15 per million—potentially reflecting genetic susceptibility, environmental factors, or enhanced case detection. Risk factors include occupational solvent exposure, prior chemotherapy or radiation, autoimmune disorders (e.g., lupus, thyroiditis), and specific HLA haplotypes (e.g., HLA-DR2). Clinically, patients present with fatigue, pallor, dyspnea (anemia), recurrent febrile infections (neutropenia), and mucocutaneous bleeding or petechiae (thrombocytopenia). Severe AA carries high mortality without treatment: median survival is <6 months untreated, with hemorrhage and sepsis being leading causes of death. Quality of life is significantly impaired—not only due to physical symptoms but also psychological burden, treatment-related side effects (e.g., immunosuppressive therapy-induced fatigue, infection risk, or GVHD post-transplant), prolonged hospitalizations, and socioeconomic strain from lost workdays and caregiving demands. Patients often experience anxiety, depression, and social isolation, especially during prolonged recovery phases or while awaiting matched donors for hematopoietic stem cell transplantation (HSCT). Early diagnosis via peripheral blood counts, reticulocyte count, and confirmatory bone marrow biopsy (showing <25% cellularity with absence of dysplasia or infiltrative disease) is critical. Prognosis depends on disease severity (classified as non-severe, severe, or very severe AA), age, comorbidities, and treatment response. With modern therapies—including immunosuppressive therapy (IST) with antithymocyte globulin [ATG] and cyclosporine, or allogeneic HSCT—5-year overall survival exceeds 80% in younger patients receiving matched sibling donor transplants and 70–75% with IST. However, relapse, clonal evolution (to MDS or AML), and chronic complications remain key challenges requiring lifelong monitoring.

# 再生障碍性贫血（AA）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

• •免疫抑制治疗（IST）：适用于≥40岁或无HLA相合供者的重型AA患者

- 费用区间：¥80,000–¥150,000（含ATG药费¥65,000–¥120,000；环孢素¥3,000–¥8,000；血药浓度监测¥1,200/次×6次） - 必查项目：骨髓穿刺活检（¥1,200）、HLA配型（¥2,800）、肝肾功能+血药浓度（¥600/次）

二、根治性治疗方案

• •异基因造血干细胞移植（allo-HSCT）：≤50岁、有HLA相合同胞供者或高分辨匹配无关供者（MUD）的重型/极重型AA首选

- 费用区间：¥350,000–¥680,000（含供者筛查¥5,000、预处理化疗¥12,000、移植病房单间日费¥1,800×30天、抗感染/成分输血等支持治疗¥150,000–¥300,000） - 术前检查：全项感染筛查（HBV/HCV/HIV/EBV/CMV）¥2,600、心肺功能评估¥3,200

三、特殊复杂情况方案

• •复发/难治性AA：加用艾曲泊帕（促血小板生成素受体激动剂）联合IST，年药费¥240,000–¥320,000；
• •合并严重感染或出血：ICU支持+广谱抗真菌/抗细菌治疗，日均费用¥12,000–¥25,000。

四、方案快速选择指南

• •预算有限/老年患者：首选IST（中档方案¥100,000内）；
• •年轻重型AA/有匹配供者：强烈推荐allo-HSCT（长期治愈率>75%）；
• •复发耐药/无供者：艾曲泊帕+IST序贯治疗，需医保谈判或慈善援助。